CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
Ibrutinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02604511
NCT02604511Phase 2Completed
CompareCT.gov

Phase II Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing

Dana-Farber Cancer Institute·interventional·Posted Nov 13, 2015·Updated Dec 7, 2022

In Brief

A Phase 2 clinical trial evaluating Ibrutinib for Waldenstrom's Macroglobulinemia. Completed, enrolled 31 participants across 2 sites.

Detailed Summary

This research study is studying a drug called ibrutinib as a possible treatment for untreated Waldenstrom's Macroglobulinemia (WM).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWaldenstrom's Macroglobulinemia
CountriesUnited States
CollaboratorsPharmacyclics LLC.

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 13, 2015
Enrollment StartJan 1, 2016
Primary CompletionNov 1, 2022
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 10.6 years ago

Interventions

Ibrutinibdrug